Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Canada / NCT05057234
Active, not recruiting Not applicable

PRecision Oncology Evidence Development in Cancer Treatment - Liquid

NCT05057234 · tracked via the Priya Life Science Canada tracker
Sponsor
British Columbia Cancer Agency
Phase
Not applicable
Started
2021-06-18
Last updated
2025-09-25

Condition(s) studied

Cancer

Investigational drug(s) / intervention(s)

FoundationOne liquid CDxQuality of life questionnaires

FoundationOne liquid CDx: FoundationOne liquid CDx testing

Quality of life questionnaires: Quality of life questionnaire - EQ5D

Study summary

The current standard of care for molecular characterization of tumors is tissue based next generation sequencing (NGS) panel. Liquid biopsies (ie blood) are of increasing interest and have been implemented as a diagnostic tool in some countries. This study compares tissue based and liquid based testing to evaluate the detection rate and cost consequence of using this new tool in BC.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Age \> 18 * Patients with metastatic malignancy * Patients undergoing tissue based molecular characterization by tissue based NGS panel Part A - Simultaneous * Tissue based NGS panel requested or reported within 4 weeks of enrolment * Patients receiving treatment at BC Cancer Part B - Sequential * Tissue based NGS oncopanel does NOT identify a somatic tier 1 variant of strong clinical significance OR fails/not feasible due to insufficient tissue * BC Cancer - Provincial (not including Vancouver Centre) Exclusion Criteria: * Patients not available for follow up * Patients who are not willing to consider systemic treatment options

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
BC Cancer Vancouver British Columbia

More British Columbia Cancer Agency trials in Canada

Preliminary Assessment of [18F]BL40 in PET/CT Scans Recruiting
Monitoring and Managing Glucose Levels in People With Pancreatic Cancer Recruiting
HELP Study - Towards High Throughput and Efficient Long-axial PET With Oral [18F]FDG Active, not recruiting
Radiotherapy 12Gy in 6 Fractions For Orbital Lymphoma Starting soon
Stereotactic Radiotherapy Versus Palliative Conventional Radiotherapy for Oligoprogressive Metastatic Cancers Recruiting

Other trials for the same condition

Attribution of Toxicities Due to Radiotherapy and Immuno-Biological Therapies Recruiting
Maitake for Integrative Cancer Care Recruiting
Secondary Prevention of VTE in Patients With Cancer and Catheter-Related Upper Extremity Deep Vein Thrombosis Recruiting
The HeLiX (Hemorrhage During Liver Resection: traneXamic Acid) Trial Active, not recruiting
Feasibility and Acceptability of Collecting Sociodemographic Data in CCTG Trials Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05057234 on ClinicalTrials.gov ↗ ← All trials in Canada